Covered recipient · General Payments record
RAY D PAGE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$2,928.38
116 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,802.71 | 114 |
| Education | $125.67 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAY D PAGE
NPI 1669422143 · CMS profile ID 166358
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
WEATHERFORD, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669422143?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAY D PAGE, NPI 1669422143, CMS profile ID 166358. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669422143?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). RAY D PAGE, NPI 1669422143, CMS profile ID 166358. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669422143?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- RAY D PAGE, NPI 1669422143, CMS profile ID 166358, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1669422143?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
116 matching records · $2,928.38 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–116 of 116.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $27.37 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144964552 | CMS |
| Gilead Sciences, Inc. | $111.33 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133641914 | CMS |
| Karyopharm Therapeutics Inc. | $18.38 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145535767 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $30.80 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086119098 | CMS |
| Lilly USA, LLC | $19.08 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135360832 | CMS |
| SpringWorks Therapeutics, Inc. | $16.11 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1085806859 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.97 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105764204 | CMS |
| PharmaEssentia USA Corporation | $32.88 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137310952 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.66 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101235971 | CMS |
| Novartis Pharmaceuticals Corporation | $20.32 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087249217 | CMS |
| SERVIER PHARMACEUTICALS LLC | $24.98 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147262867 | CMS |
| Novartis Pharmaceuticals Corporation | $24.96 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087249219 | CMS |
| Stemline Therapeutics Inc. | $21.48 | 01/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142963298 | CMS |
| Janssen Scientific Affairs, LLC | $35.53 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078861011 | CMS |
| ADC Therapeutics America, Inc. | $16.83 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121185706 | CMS |
| Astellas Pharma US Inc | $27.29 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139328276 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $217,764.25 | 44 |
| PY2024 | Principal investigator | $263,572.52 | 32 |
| PY2023 | Principal investigator | $731,969.93 | 60 |
| PY2022 | Principal investigator | $457,538.32 | 38 |
| PY2021 | Principal investigator | $142,852.05 | 38 |
| PY2020 | Principal investigator | $284,810.15 | 80 |
| PY2019 | Recipient | $5,663.00 | 2 |
| PY2019 | Principal investigator | $286,425.24 | 49 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
44 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,550.00 | 12/11/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601424 |
| Principal investigator 1 | Eli Lilly and Company | $2,082.00 | 12/09/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CONSULTANTS P A | CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1187885474 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 11/26/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 11/25/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184264345 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 11/24/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601421 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 11/14/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132417 |
| Principal investigator 1 | Incyte Corporation | $1,056.40 | 10/30/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601417 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 10/29/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192183111 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 10/20/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183097 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,400.00 | 10/09/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183073 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 10/09/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183093 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 09/26/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132450 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/26/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132423 |
| Principal investigator 1 | Eli Lilly and Company | $478.00 | 07/28/2025 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CONSULTANTS P A | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187887100 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,500.00 | 07/25/2025 | Non-covered Recipient Entity CENTER FOR CANCER AND BLOOD DISORDE | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190312341 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 07/24/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132438 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 06/23/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132461 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 05/22/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601411 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 05/16/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132465 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 05/13/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192183106 |
| Principal investigator 1 | Incyte Corporation | $240.00 | 05/08/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601408 |
| Principal investigator 1 | Incyte Corporation | $1,969.35 | 05/08/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,250.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,000.00 | 05/02/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191981 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,034.00 | 04/17/2025 | Non-covered Recipient Entity Oncology Hematology Consultants, Pa | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223375615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,300.00 | 03/27/2025 | Non-covered Recipient Entity Oncology Hematology Consultants Pa | DS1062-A-U301 | No dispute reported | 06/30/2026 | 1223375607 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132456 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,000.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183079 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $20,000.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183083 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183088 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183101 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183132 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183137 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,750.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183141 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183145 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 02/24/2025 | Non-covered Recipient Entity ONEONCOLOGY RESEARCH NETWORK LLC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192183149 |
| Principal investigator 1 | Incyte Corporation | $528.20 | 02/20/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601432 |
| Principal investigator 1 | Incyte Corporation | $12,338.00 | 02/13/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1240601428 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 02/04/2025 | Non-covered Recipient Entity ONEONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA | No dispute reported | 06/30/2026 | 1192132444 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $26,750.00 | 02/03/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton | No dispute reported | 06/30/2026 | 1185543815 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,000.00 | 01/29/2025 | Non-covered Recipient Entity THE ONEONCOLOGY RESEARCH NETWORK LLC | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) | No dispute reported | 06/30/2026 | 1185543813 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $32,168.30 | 01/10/2025 | Non-covered Recipient Entity THE CENTER FOR CANCER AND BLOOD DISORDERS | A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer | No dispute reported | 06/30/2026 | 1185543811 |